Efficacy and Safety Evaluation in Recurrent Wheezing Attacks (MV130)
Randomized Double-blind Placebo-controlled, Parallel, Multi Centre Clinical Trial of Sublingual Bacterial Vaccine in Children With Recurrent Bronchospasm (Wheezing Attacks) for the Evaluation of Efficacy, Security and Clinical Impact.
Sponsor: Inmunotek S.L.
A PHASE3 clinical study on Bronchospasm; Bronchiolitis and Bronchospasm; Bronchitis, this trial is completed. The trial is conducted by Inmunotek S.L. and has accumulated 11 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Oct 2020 — Dec 2020 [monthly]
Completed PHASE3
-
May 2020 — Oct 2020 [monthly]
Completed PHASE3
-
Jun 2018 — May 2020 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Inmunotek S.L.
- Unidad de Investigacion Medica en Epidemiologia Clinica
For direct contact, visit the study record on ClinicalTrials.gov .